betadex and Depressive-Disorder--Major

betadex has been researched along with Depressive-Disorder--Major* in 2 studies

Reviews

1 review(s) available for betadex and Depressive-Disorder--Major

Article	Year
Advances in treatment for postpartum major depressive disorder. Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:14 Topics: Antidepressive Agents; beta-Cyclodextrins; Depression, Postpartum; Depressive Disorder, Major; Drug Combinations; Drug Monitoring; Estrogens; Female; Humans; Oxytocin; Pregnanolone; Randomized Controlled Trials as Topic; Transcranial Magnetic Stimulation; Treatment Outcome; United States	2020

Article

Year

Advances in treatment for postpartum major depressive disorder.

Expert opinion on pharmacotherapy, 2020, Volume: 21, Issue:14

Topics: Antidepressive Agents; beta-Cyclodextrins; Depression, Postpartum; Depressive Disorder, Major; Drug Combinations; Drug Monitoring; Estrogens; Female; Humans; Oxytocin; Pregnanolone; Randomized Controlled Trials as Topic; Transcranial Magnetic Stimulation; Treatment Outcome; United States

2020

Other Studies

1 other study(ies) available for betadex and Depressive-Disorder--Major

Article	Year
GABA Cell, 2019, 01-10, Volume: 176, Issue:1-2 During the postpartum period, the brain's inhibitory GABAA receptors may not recover in time following their reduced numbers during pregnancy. This is likely the cause of postpartum depression prevalent in ∼12% of childbearing women. A new therapy for this condition consists of administering a synthetic neurosteroid during the postpartum period to alleviate the mood disorder. To view this Bench to Bedside, open or download the PDF. Topics: Adult; beta-Cyclodextrins; Depression, Postpartum; Depressive Disorder, Major; Drug Combinations; Female; Humans; Mood Disorders; Neurotransmitter Agents; Postpartum Period; Pregnancy; Pregnanolone; Prevalence; Receptors, GABA-A	2019

Article

Year

GABA

Cell, 2019, 01-10, Volume: 176, Issue:1-2

During the postpartum period, the brain's inhibitory GABAA receptors may not recover in time following their reduced numbers during pregnancy. This is likely the cause of postpartum depression prevalent in ∼12% of childbearing women. A new therapy for this condition consists of administering a synthetic neurosteroid during the postpartum period to alleviate the mood disorder. To view this Bench to Bedside, open or download the PDF.

Topics: Adult; beta-Cyclodextrins; Depression, Postpartum; Depressive Disorder, Major; Drug Combinations; Female; Humans; Mood Disorders; Neurotransmitter Agents; Postpartum Period; Pregnancy; Pregnanolone; Prevalence; Receptors, GABA-A

2019